<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28380047</article-id><article-id pub-id-type="pmc">5381881</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0174588</article-id><article-id pub-id-type="publisher-id">PONE-D-16-48747</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Heart</subject><subj-group><subject>Myocardium</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Heart</subject><subj-group><subject>Myocardium</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Reactions</subject><subj-group><subject>Oxidation-Reduction Reactions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Electrochemistry</subject><subj-group><subject>Oxidation-Reduction Reactions</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Ischemia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Heart</subject><subj-group><subject>Aortic Valve</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Cardiovascular Anatomy</subject><subj-group><subject>Heart</subject><subj-group><subject>Aortic Valve</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Dyslipidemia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurochemicals</subject><subj-group><subject>Nitric Oxide</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Neurochemistry</subject><subj-group><subject>Neurochemicals</subject><subj-group><subject>Nitric Oxide</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Antioxidants</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Response of the human myocardium to ischemic injury and preconditioning: The role of cardiac and comorbid conditions, medical treatment, and basal redox status</article-title><alt-title alt-title-type="running-head">Human myocardium, ischemic injury, preconditioning and basal redox status</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cas&#x000f3;s</surname><given-names>Kelly</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ferrer-Curriu</surname><given-names>Gemma</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Soler-Ferrer</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>P&#x000e9;rez</surname><given-names>Mar&#x000ed;a L</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Permanyer</surname><given-names>Eduard</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Blasco-Lucas</surname><given-names>Arnau</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gracia-Baena</surname><given-names>Juan Manuel</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Castro</surname><given-names>Miguel A</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sureda</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barquinero</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0888-976X</contrib-id><name><surname>Gali&#x000f1;anes</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Reparative Therapy of the Heart, Vall d&#x02019;Hebron Research Institute (VHIR), University Hospital Vall d&#x02019;Hebron, Autonomous University of Barcelona (UAB), Barcelona, Spain</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Department of Cardiac Surgery, University Hospital Vall d&#x02019;Hebron, Autonomous University of Barcelona (UAB), Barcelona, Spain</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Gene &#x00026; Cell and Therapy Laboratory VHIR, UAB, Barcelona, Spain</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Eckle</surname><given-names>Tobias</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Colorado Denver, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> MG.</p></list-item><list-item><p><bold>Data curation:</bold> EP CS AB MAC JMGB JB.</p></list-item><list-item><p><bold>Formal analysis:</bold> KC GFC.</p></list-item><list-item><p><bold>Funding acquisition:</bold> MG.</p></list-item><list-item><p><bold>Investigation:</bold> KC GFC PSF.</p></list-item><list-item><p><bold>Methodology:</bold> MG KC.</p></list-item><list-item><p><bold>Project administration:</bold> KC.</p></list-item><list-item><p><bold>Software:</bold> MP.</p></list-item><list-item><p><bold>Supervision:</bold> MG KC.</p></list-item><list-item><p><bold>Validation:</bold> KC GFC.</p></list-item><list-item><p><bold>Visualization:</bold> KC.</p></list-item><list-item><p><bold>Writing &#x02013; original draft:</bold> KC GFC.</p></list-item><list-item><p><bold>Writing &#x02013; review &#x00026; editing:</bold> MG.</p></list-item></list>
</p></fn><corresp id="cor001">* E-mail: <email>manuel.galinanes@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>5</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>4</issue><elocation-id>e0174588</elocation-id><history><date date-type="received"><day>12</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>2</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Cas&#x000f3;s et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Cas&#x000f3;s et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0174588.pdf"/><abstract><sec id="sec001"><title>Background</title><p>The diseased human myocardium is highly susceptible to ischemia/reoxygenation (I/R)-induced injury but its response to protective interventions such as ischemic preconditioning (IPreC) is unclear. Cardiac and other pre-existing clinical conditions as well as previous or ongoing medical treatment may influence the myocardial response to I/R injury and protection. This study investigated the effect of both on myocardial susceptibility to I/R-induced injury and the protective effects of IPreC.</p></sec><sec id="sec002"><title>Methods and results</title><p>Atrial myocardium from cardiac surgery patients (n = 300) was assigned to one of three groups: aerobic control, I/R alone, and IPreC. Lactate dehydrogenase leakage, as a marker of cell injury, and cell viability were measured. The basal redox status was determined in samples from 90 patients.</p><p>The response to I/R varied widely. Myocardium from patients with aortic valve disease was the most susceptible to injury whereas myocardium from dyslipidemia patients was the least susceptible. Tissue from females was better protected than tissue from males. Myocardium from patients with mitral valve disease was the least responsive to IPreC. The basal redox status was altered in the myocardium from patients with mitral and aortic valve disease.</p></sec><sec id="sec003"><title>Conclusions</title><p>The response of the myocardium to I/R and IPreC is highly variable and influenced by the underlying cardiac pathology, dyslipidemia, sex, and the basal redox status. These results should be taken into account in the design of future clinical studies on the prevention of I/R injury and protection.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>12/00119</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0888-976X</contrib-id><name><surname>Gali&#x000f1;anes</surname><given-names>Manuel</given-names></name></principal-award-recipient></award-group><funding-statement>This study was supported by the Instituto de Salud Carlos III (FIS) [grant number 12/00119].</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec004"><title>Introduction</title><p>Cardiovascular diseases are the most prevalent health problem worldwide and the major cause of morbidity and mortality [<xref rid="pone.0174588.ref001" ref-type="bibr">1</xref>]. According to the WHO, in 2012 ischemic heart diseases caused 17.5 million deaths. Prolonged ischemia, such as occurs during myocardial infarction, causes lactate accumulation, alterations in ion-transport mechanisms, and eventually cardiomyocyte death through apoptosis and necrosis. However, oxygen restoration during reperfusion creates a large burst of reactive oxygen species production and calcium overload [<xref rid="pone.0174588.ref002" ref-type="bibr">2</xref>], causing additional myocardial damage. In fact, ischemic/reperfusion (I/R) injury is one of the main risk factors during heart surgery [<xref rid="pone.0174588.ref003" ref-type="bibr">3</xref>&#x02013;<xref rid="pone.0174588.ref005" ref-type="bibr">5</xref>], especially in older patients and those with underlying comorbidities (e.g., diabetes) [<xref rid="pone.0174588.ref006" ref-type="bibr">6</xref>]. Over the last three decades, major efforts have been aimed at understanding the mechanisms of I/R-induced injury and developing strategies to protect the human myocardium. Nonetheless, much remains to be learned.</p><p>One of the main mechanisms of myocardial injury during I/R is oxidative and nitrosative stress, in which there is an imbalance between oxidant and antioxidant species that favors the former [<xref rid="pone.0174588.ref007" ref-type="bibr">7</xref>]. However, whether the basal redox status prior to the ischemic episode plays a significant role in I/R-induced myocardial injury is unknown. The main objectives of the present study were: (1) to determine myocardial susceptibility to I/R injury and the protective capacity of IPreC using myocardium obtained from patients undergoing elective cardiac surgery; (2) to investigate the effect of cardiac and other comorbidities and of medical treatment on I/R-induced injury and IPreC, and (3) to examine the role of the basal redox status in both these processes.</p></sec><sec sec-type="materials|methods" id="sec005"><title>Methods</title><sec id="sec006"><title>Study population</title><p>The study was approved by the Ethics Committee of Vall d'Hebron University Hospital (ID-RTF065) and conducted according to the principles expressed in the Helsinki Declaration. Written informed consent was obtained from each patient. The right atrial appendage was obtained from 300 patients undergoing elective cardiac surgery who were prospectively recruited without any exclusion criteria. Because of physical limitations, all patients had a sedentary life style before surgery. Demographic data, the presence of cardiovascular risk factors, and the medical treatment history of each patient were recorded.</p></sec><sec id="sec007"><title>Human tissue collection and study groups</title><p>The right atrial appendages were collected in Krebs Henseleit Hepes (KHH) buffer containing (in mM): 118 NaCl, 4.8 KCl, 327.2 NaHCO, 1.2 MgCl<sub>2</sub>, 1 KH<sub>2</sub>PO<sub>4</sub>, 20 HEPES (Sigma, St. Louis, MO), pH 7.4 at 4&#x02013;5&#x000b0;C. Briefly, the appendage was mounted epicardial surface face down onto a ground-glass plate and then sliced using surgical skin-graft blades (Swann-Morton, UK) to a thickness of 300&#x02013;500 &#x003bc;m. The tissues slices (weight 30&#x02013;50 mg) were kept moist throughout the procedure. Muscle pieces immediately frozen at &#x02212;80&#x000b0;C were later used for the determination of basal redox status. The remaining muscle pieces were placed into a shaking water bath at 37&#x000b0;C and equilibrated for 30&#x02013;40 min at 37&#x000b0;C in oxygenated buffer KHH containing 10 mM glucose and 1.25 mM CaCl<sub>2</sub>, pH 7.4.</p><p>The samples were then allocated to one of the following groups (<xref ref-type="fig" rid="pone.0174588.g001">Fig 1</xref>): (1) aerobic control (AC), in which the samples were incubated for 210 min in oxygenated KHH buffer (pH 7.4); (2) simulated ischemia/reoxygenation (I/R alone), induced by bubbling the incubation medium with 95% N<sub>2</sub>&#x02212;5% CO<sub>2</sub> (pH 6.8&#x02013;7.0) and replacing <sc>d</sc>-glucose with 2-deoxy-<sc>d</sc>-glucose (Sigma, St. Louis, MO), as previously described [<xref rid="pone.0174588.ref008" ref-type="bibr">8</xref>]; and (3) IPreC, induced by 5 min of ischemia followed by 5 min of reoxygenation, applied before 90 min of ischemia and followed by 120 min of reoxygenation. In a previous study, we demonstrated that this protocol confers the greatest protection under laboratory conditions [<xref rid="pone.0174588.ref009" ref-type="bibr">9</xref>].</p><fig id="pone.0174588.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0174588.g001</object-id><label>Fig 1</label><caption><title>Experimental protocol.</title><p>Tissues in all groups were equilibrated for 30&#x02013;40 min at 37&#x000b0;C in aerobic conditions. Muscle tissues were either maintained under aerobic conditions (AC) for the entire experimental period or subjected to 90 min of ischemia followed by 120 min of ischemia/reoxygenation (I/R alone) or preconditioned (IPreC) with 5 min of ischemia and 5 min of reoxygenation.</p></caption><graphic xlink:href="pone.0174588.g001"/></fig></sec><sec id="sec008"><title>Assessment of tissue injury and tissue viability</title><p>Tissue injury was assessed by the release of lactate dehydrogenase (LDH), which converts pyruvate to lactate, into the incubation medium at the end of the 120-min reoxygenation period. The absorbance was measured at a wavelength of 340 nm using a MultiSkan FC spectrometer (Thermo Fisher Scientific, Waltham, MA). The results were expressed as arbitrary units (AU)/g tissue wet wt.</p><p>The viability of the muscle tissue was assessed at the end of the 120-min reoxygenation period by the reduction of 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma, St. Louis, MO) to a blue formazan product, the absorbance of which was measured at 550 nm using a MultiSkan FC spectrometer (Thermo Fisher Scientific, Waltham, MA). The results were expressed as AU/g wet wt.</p></sec><sec id="sec009"><title>Protein extraction from myocardial tissues</title><p>Basal myocardial antioxidant capacity and oxidative and nitrosative stress were assessed in 90 myocardial tissue samples taken from unselected patients. After the samples were pulverized in liquid N<sub>2</sub>, they were transferred to phosphate buffer saline solution, pH 7.4 (15% v/w) (Sigma, St. Louis, MO) and sonicated. After 30 min on ice, the homogenates were centrifuged at 17000<italic>g</italic> for 15 min at 4&#x000b0;C. The supernatants were collected and used for the analyses. Protein amounts were quantified using the DC<sup>&#x02122;</sup> protein assay (Bio-Rad, Hercules, CA).</p></sec><sec id="sec010"><title>Assessment of total antioxidant capacity (TAC)</title><p>The total antioxidant capacity was assessed using the Oxiselect<sup>&#x02122;</sup> assay kit (Cell Biolabs, San Diego, CA). The copper ion reagent (Cu<sup>2+</sup>) or a known concentration of uric acid was added to the samples. Upon reduction, Cu<sup>2+</sup> reacts with a chromogenic reagent that produces an orange colored product. The absorbance of this product at 490 nm was measured using a MultiSkan FC spectrometer (Thermo Fisher Scientific, Waltham, MA). The results were expressed as mM of uric acid/mg protein.</p></sec><sec id="sec011"><title>Manganese superoxide dismutase (MnSOD or SOD<sub>2</sub>) and catalase expression</title><p>Western blot experiments were conducted to measure MnSOD or SOD<sub>2</sub> and catalase expression. Tissue sample were homogenized in lysis buffer (2% SDS, 10% glycerol, either 62.5 mM Trizma base, pH 6.8, or Tris HCl, protease, and phosphatase inhibitor). For western blot analysis, 80 &#x003bc;g of MnSOD and catalase proteins were separated electrophoretically on a 4&#x02013;20% polyacrylamide gel and then transferred onto a nitrocellulose membrane using a semi-dry electric transfer device (Bio-Rad Laboratories, Hercules, CA). The membranes were then blocked in 5% nonfat dry milk in Tris-buffered saline and incubated with an anti-catalase or anti-MnSOD rabbit polyclonal antibody (EMD Millipore Corporation, San Diego, CA and Sigma, St. Louis, MO, respectively). Incubation with an anti-actinin goat polyclonal antibody served as the normalization control. The secondary antibodies were goat anti-rabbit (Sigma) and donkey anti-goat (Abcam, Cambridge, UK) conjugated with horseradish peroxidase. The bands were visualized using Clarity<sup>&#x02122;</sup> Western ECL (Bio-Rad Laboratories, Hercules, CA); the images were captured on a luminescent image analyzer LAS-3000 (FujiFilm Life Science, Stamford, CT). Individual MnSOD and catalase bands were quantified by densitometric scanning using the Image J program. The results were expressed as arbitrary densitometric units (ADU).</p></sec><sec id="sec012"><title>Determination of superoxide anion production (O<sub>2</sub><sup>.&#x02212;</sup>)</title><p>The generation of O<sub>2</sub><sup>.&#x02212;</sup> was determined using 2,3-dimethoxy-1,4-naphtoquinone (DMNQ), which is a redox-cycling agent that induces intracellular O<sub>2</sub><sup>.&#x02212;</sup> formation. The reaction mixture, containing (in mM) 50 potassium phosphate, 1 ethylene diaminetetraacetic acid (EDTA), and 1 DMNQ (Sigma, St. Louis, MO), was incubated with 10 &#x003bc;l of tissue homogenate at 37&#x000b0;C for 3 h. Thereafter, native coelenterazine (Sigma, St. Louis, MO), which emits light from enzyme-independent oxidation in the presence of O<sub>2</sub><sup>.&#x02212;</sup> and peroxynitrite, was added at a concentration of 100 &#x003bc;M. The emitted luminescence was measured with Gene 5 (Biotek, Winooski, VT). The results were expressed as luminescence units (LU)/&#x003bc;g protein.</p></sec><sec id="sec013"><title>Determination of thiobarbituric-acid-reactive substances (TBARS)</title><p>Malondialdehyde (MDA) formation was used as an indicator of TBARS production. A mixture containing tissue homogenate, 0.5% butyl hydroxy toluene, 0.14 mM ethylene-diamine-tetra-acetic acid, 40% trichloro-acetic acid, and 0.67% thiobarbituric acid (TBA) was boiled at 100&#x000b0;C for 10 min to start the reaction. TBA reacts with MDA to yield a pink product. Aqueous and organic phases were separated by the addition of acetic glacial acid and chloroform followed by centrifugation at 1700<italic>g</italic> for 30 min. The absorbance of the organic phase was measured at 540 nm. The MDA concentration was calculated from a standard curve of 1,1,3,3-tetraethoxypropane. The results were expressed as &#x003bc;M TBARS/mg protein.</p></sec><sec id="sec014"><title>Determination of nitric oxide (NO) bioavailability</title><p>The bioavailability of NO was assessed using a colorimetric assay kit (Cayman, Ann Arbor, MI) performed according to the manufacturer&#x02019;s instructions. The samples were incubated with nitrate reductase, which converts nitrates to nitrites. The latter react with the Griess reagent to yield a colored azo dye product, the absorbance of which was measured at 540 nm using a MultiSkan FC spectrometer (Thermo Fisher Scientific Waltham, MA). The results were expressed as &#x003bc;M NO/mg protein.</p></sec><sec id="sec015"><title>Determination of 3-nitrotyrosine</title><p>The OxySelect<sup>&#x02122;</sup> Elisa kit (Cell Biolabs, San Diego, CA) was used to measure 3-nitrotyrosine, a product of tyrosine nitration by peroxynitrite, production. The assay was carried out according to the manufacturer&#x02019;s instructions. The results were expressed as nM 3-nitrotyrosine/mg protein.</p></sec><sec id="sec016"><title>Statistical analysis</title><p>The results were expressed as the mean &#x000b1; SEM. ANOVA and the Mann-Whitney test were used to compare the means between groups. Linear regression and logistic binary regression were used to compare the influence of the associated comorbidities and medical treatment. The redox indexes were analyzed using the Kruskal Wallis test, followed by a post-hoc Dunn&#x02019;s test when indicated. Statistical analyses were performed using the SPSS 20 and Graph Pad Prism 6. A P value &#x0003c; 0.05 was considered to indicate statistical significance.</p></sec></sec><sec sec-type="results" id="sec017"><title>Results</title><p><xref ref-type="table" rid="pone.0174588.t001">Table 1</xref> summarizes the demographic data from the donor patients (n = 300).</p><table-wrap id="pone.0174588.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0174588.t001</object-id><label>Table 1</label><caption><title>Demographic data of study patients.</title></caption><alternatives><graphic id="pone.0174588.t001g" xlink:href="pone.0174588.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">N = 300 (ratio in %)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">94(31)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">206(69)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">65&#x000b1;12</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">118(39)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Insulin-dependent</td><td align="center" rowspan="1" colspan="1">29(10)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Non insulin-dependent</td><td align="center" rowspan="1" colspan="1">66(22)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">161(54)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">207(69)</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery disease</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">123(41)</td></tr><tr><td align="left" rowspan="1" colspan="1">Aneurysm of ascending aorta</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">43(14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Interatrial communication (ostium secundum)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3(1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricular ejection fraction</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;40</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">278(93)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;40</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">22(7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Paroxystic</td><td align="center" rowspan="1" colspan="1">17(6)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Permanent</td><td align="center" rowspan="1" colspan="1">27(9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic valve disease</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">175(58)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mitral valve disease</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">46(15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tricuspid valve disease</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10(3)</td></tr></tbody></table></alternatives></table-wrap><sec id="sec018"><title>Susceptibility of the human myocardium to I/R-induced injury</title><p><xref ref-type="fig" rid="pone.0174588.g002">Fig 2A1 and 2B1</xref> shows the overall mean values for LDH and cell viability, respectively, for the three study groups (the mean &#x000b1; SEM for all results are shown in Table A in <xref ref-type="supplementary-material" rid="pone.0174588.s001">S1 File</xref>). I/R alone induced a significant increase in LDH and a significant decrease in viability compared with the aerobic controls. In addition, IPreC significantly reduced the ischemic damage, evidenced by the reduction in LDH and the greater cell viability. <xref ref-type="fig" rid="pone.0174588.g002">Fig 2A2 and 2B2</xref> show the wide-ranging response of human myocardium to I/R injury, as in some tissues there was only a small amount of LDH leakage and only a small decrease in viability, whereas in other tissues the LDH leakage and viability were substantially worse. As expected, the correlation between I/R injury and protection by IPreC was positive for LDH leakage and viability.</p><fig id="pone.0174588.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0174588.g002</object-id><label>Fig 2</label><caption><title>Lactate dehydrogenase (LDH) leakage (A1) and 3-(4,5-dimethyl thiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) reduction (B1) and the correlation between IPreC and I/R alone for LDH release (A2) and MTT reduction (B2) of human myocardium muscles (n = 300 per group) subjected to 250 min of aerobic condictions (AC), 90 min of ischemia followed by 120 min of reoxygenation (I/R alone), or ischemic preconditioning (IPreC) induced by 5 min of ischemia followed by 5 min of reoxygenation prior to the 90 min of ischemia.</title><p>The mean values are shown. *<italic>p</italic> &#x0003c; 0.05 vs AC group and &#x02020;<italic>p</italic> &#x0003c; 0.05 vs I/R alone group.</p></caption><graphic xlink:href="pone.0174588.g002"/></fig></sec><sec id="sec019"><title>Broad-spectrum response of human myocardium to IPreC</title><p><xref ref-type="fig" rid="pone.0174588.g003">Fig 3A and 3B</xref> also demonstrates the wide-ranging response of human myocardium to protection by IPreC. Based on a comparison of the data from the IPreC and I/R alone groups, (negative LDH values and positive viability), the degree of protection was greater in the presence of more severe ischemic injury. The results also showed that muscle tissue with less ischemic injury either did not respond to preconditioning or was more susceptible to damage during IPreC. Thus, in 22% of the samples analyzed, the LDH and viability values of the IPreC group were worse than those of the I/R alone group. These findings suggest that protective interventions such as IPreC are unwarranted in patients with less myocardial damage.</p><fig id="pone.0174588.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0174588.g003</object-id><label>Fig 3</label><caption><title>Correlation between IPreC-I/R alone and I/R alone values for LDH release (A) and MTT reduction (B) in human myocardial muscles (n = 300), subjected to 90 min of normothemic ischemia followed by 120 min of reoxygenation (I/R alone) and ischemic preconditioning (IPreC) induced by 5 min of ischemia followed by 5 min of reoxygenation prior to the 90 min of ischemia.</title><p>*<italic>p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="pone.0174588.g003"/></fig></sec><sec id="sec020"><title>The role of cardiac pathologies, comorbidities, and medical treatment</title><p>The effects of underlying cardiac pathologies, comorbidities, and medical treatment on myocardial susceptibility to I/R-induced injury and the capacity for cardioprotection by IPreC were analyzed. Myocardium from patients with aortic valve disease was more susceptible to I/R injury than myocardium from patients with other cardiac pathologies, whereas myocardium from patients with dyslipidemia was the least susceptible (<xref ref-type="table" rid="pone.0174588.t002">Table 2</xref>). Interestingly, comorbidities and medical treatment did not influence the susceptibility of the myocardium to ischemia (data shown in Tables B and C in <xref ref-type="supplementary-material" rid="pone.0174588.s001">S1 File</xref>). The protection conferred by IPreC was significantly better in myocardial tissues from females than from males. Among the cardiac diseases, myocardium from patients with mitral valve disease was the least responsive to IPreC protection (<xref ref-type="table" rid="pone.0174588.t003">Table 3</xref>).</p><table-wrap id="pone.0174588.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0174588.t002</object-id><label>Table 2</label><caption><title>Conditions affecting the susceptibility to ischemia/reoxygenation (I/R)-induced injury obtained by substracting the LDH values of the AC group from the I/R alone group for each individual patients and then compared with the mean value of the remainder study population.</title></caption><alternatives><graphic id="pone.0174588.t002g" xlink:href="pone.0174588.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Condition</th><th align="left" rowspan="1" colspan="1">N</th><th align="left" rowspan="1" colspan="1">Average LDH (AU/g. wet wt)</th><th align="left" rowspan="1" colspan="1">P&#x02013;value<xref ref-type="table-fn" rid="t002fn001">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">With aortic valve disease</td><td align="right" rowspan="1" colspan="1">137</td><td align="char" char="." rowspan="1" colspan="1">1.1</td><td align="char" char="." rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" rowspan="1" colspan="1">Without aortic valve disease</td><td align="right" rowspan="1" colspan="1">163</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">With dyslipidemia</td><td align="right" rowspan="1" colspan="1">161</td><td align="char" char="." rowspan="1" colspan="1">0.9</td><td align="char" char="." rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">Without dyslipidemia</td><td align="right" rowspan="1" colspan="1">139</td><td align="char" char="." rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><italic>*p</italic> values were calculated using the Mann Whitney test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0174588.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0174588.t003</object-id><label>Table 3</label><caption><title>Conditions affecting the capacity for cardioprotection by preconditioning (IPreC) obtained by substracting the LDH values of the I/R alone group from the IPreC group for each individual patients and then compared with the mean value of the remainder study population.</title></caption><alternatives><graphic id="pone.0174588.t003g" xlink:href="pone.0174588.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Condition</th><th align="left" rowspan="1" colspan="1">N</th><th align="left" rowspan="1" colspan="1">Average LDH (AU/g. wet wt)</th><th align="left" rowspan="1" colspan="1">P&#x02013;value<xref ref-type="table-fn" rid="t003fn001">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">94</td><td align="char" char="." rowspan="1" colspan="1">-0.50</td><td align="char" char="." rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">206</td><td align="char" char="." rowspan="1" colspan="1">-0.30</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">With mitral valve disease</td><td align="center" rowspan="1" colspan="1">46</td><td align="char" char="." rowspan="1" colspan="1">-0.12</td><td align="char" char="." rowspan="1" colspan="1">0.038</td></tr><tr><td align="left" rowspan="1" colspan="1">Without mitral valve disease</td><td align="center" rowspan="1" colspan="1">254</td><td align="char" char="." rowspan="1" colspan="1">-0.44</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><italic>*p</italic> values were calculated using the Mann Whitney test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec021"><title>Basal myocardial redox status and its influence on the response to ischemia and IPreC</title><p>Oxygen and nitrogen free radicals play important roles in ischemic injury, in the signal transduction mechanism that confers myocardial protection [<xref rid="pone.0174588.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0174588.ref011" ref-type="bibr">11</xref>], and in the pathogenesis and development of cardiovascular diseases, particularly atherosclerosis [<xref rid="pone.0174588.ref012" ref-type="bibr">12</xref>]. To investigate whether the basal redox status influences the susceptibility of the human myocardium to I/R injury and whether IPreC has a protective effect, tissue levels of NO, MDA, 3-nitrotyrosine, TAC, O<sub>2</sub><sup>.&#x02212;</sup>, MnSOD, and catalase were measured in atrial muscle tissue from 90 unselected patients undergoing cardiac surgery. As seen in <xref ref-type="table" rid="pone.0174588.t004">Table 4</xref>, myocardium from patients with aortic valve disease, shown in the above-described experiment to be more susceptible to I/R injury, had lower TAC and higher catalase values than myocardium from patients without aortic valve disease. <xref ref-type="table" rid="pone.0174588.t004">Table 4</xref> also shows that the MnSOD content was significantly higher in myocardium from patients with mitral valve disease, whose tissue was less responsive to IPreC-mediated protection, than in myocardium from patients without mitral valve pathologies.</p><table-wrap id="pone.0174588.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0174588.t004</object-id><label>Table 4</label><caption><title>Indexes of basal redox status in human right atrial tissue (n = 90) from patients with conditions that affect myocardial susceptibilility to I/R-induced injury and the capacity for IPreC-mediated protection.</title></caption><alternatives><graphic id="pone.0174588.t004g" xlink:href="pone.0174588.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Index</th><th align="center" rowspan="1" colspan="1">With AVD</th><th align="center" rowspan="1" colspan="1">Without AVD</th><th align="center" rowspan="1" colspan="1">With DLP</th><th align="center" rowspan="1" colspan="1">Without DLP</th><th align="center" rowspan="1" colspan="1">Female</th><th align="center" rowspan="1" colspan="1">Male</th><th align="center" rowspan="1" colspan="1">With MVD</th><th align="center" rowspan="1" colspan="1">Without MVD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No (&#x003bc;M/mg prot)</td><td align="center" rowspan="1" colspan="1">52.25&#x000b1;5.3</td><td align="center" rowspan="1" colspan="1">45.68&#x000b1;5.4</td><td align="center" rowspan="1" colspan="1">48.69&#x000b1;4.8</td><td align="center" rowspan="1" colspan="1">51.39&#x000b1;6.5</td><td align="center" rowspan="1" colspan="1">48.12&#x000b1;4.6</td><td align="center" rowspan="1" colspan="1">52.58&#x000b1;6.8</td><td align="center" rowspan="1" colspan="1">49.53&#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">49.81&#x000b1;4.4</td></tr><tr><td align="left" rowspan="1" colspan="1">MDA (&#x003bc;M/mg prot)</td><td align="center" rowspan="1" colspan="1">25.54&#x000b1;3.0</td><td align="center" rowspan="1" colspan="1">23.80&#x000b1;0.2</td><td align="center" rowspan="1" colspan="1">24.95&#x000b1;2.4</td><td align="center" rowspan="1" colspan="1">24.57&#x000b1;3.5</td><td align="center" rowspan="1" colspan="1">27.19&#x000b1;2.8</td><td align="center" rowspan="1" colspan="1">20.61&#x000b1;2.4</td><td align="center" rowspan="1" colspan="1">24.26&#x000b1;4.1</td><td align="center" rowspan="1" colspan="1">24.92&#x000b1;2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">3-NT (nM/mg prot)</td><td align="center" rowspan="1" colspan="1">229.33&#x000b1;25.7</td><td align="center" rowspan="1" colspan="1">187.63&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">223.34&#x000b1;29.3</td><td align="center" rowspan="1" colspan="1">202.96&#x000b1;16.9</td><td align="center" rowspan="1" colspan="1">234.32&#x000b1;25.5</td><td align="center" rowspan="1" colspan="1">176&#x000b1;14.9</td><td align="center" rowspan="1" colspan="1">165.38&#x000b1;19.7</td><td align="center" rowspan="1" colspan="1">224.93&#x000b1;20.8</td></tr><tr><td align="left" rowspan="1" colspan="1">O<sub>2</sub><sup>.-</sup> (UL/&#x003bc;g prot)</td><td align="center" rowspan="1" colspan="1">27.51&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">29.84&#x000b1;17.6</td><td align="center" rowspan="1" colspan="1">28.21&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">28.20&#x000b1;2.0</td><td align="center" rowspan="1" colspan="1">28.00&#x000b1;1.4</td><td align="center" rowspan="1" colspan="1">28.67&#x000b1;1.8</td><td align="center" rowspan="1" colspan="1">30.23&#x000b1;2.5</td><td align="center" rowspan="1" colspan="1">27.73&#x000b1;1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">TAC (mM Uric acid/&#x003bc;g prot)</td><td align="center" rowspan="1" colspan="1"><bold><italic>1</italic>.<italic>6&#x000b1;0</italic>.<italic>08</italic></bold><xref ref-type="table-fn" rid="t004fn002">*</xref></td><td align="center" rowspan="1" colspan="1">1.89&#x000b1;2.1</td><td align="center" rowspan="1" colspan="1">1.70&#x000b1;0.07</td><td align="center" rowspan="1" colspan="1">1.76&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">1.68&#x000b1;0.07</td><td align="center" rowspan="1" colspan="1">1.80&#x000b1;0.12</td><td align="center" rowspan="1" colspan="1">1.93&#x000b1;0.19</td><td align="center" rowspan="1" colspan="1">1.67&#x000b1;0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">MnSOD (ADU)</td><td align="center" rowspan="1" colspan="1">0.89&#x000b1;0.04</td><td align="center" rowspan="1" colspan="1">0.88&#x000b1;0.1</td><td align="center" rowspan="1" colspan="1">0.87&#x000b1;0.04</td><td align="center" rowspan="1" colspan="1">0.91&#x000b1;0.04</td><td align="center" rowspan="1" colspan="1">0.85&#x000b1;0.03</td><td align="center" rowspan="1" colspan="1">0.96&#x000b1;0.04</td><td align="center" rowspan="1" colspan="1"><bold><italic>1</italic>.<italic>02&#x000b1;0</italic>.<italic>07</italic></bold><xref ref-type="table-fn" rid="t004fn002">*</xref></td><td align="center" rowspan="1" colspan="1">0.86&#x000b1;0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">CAT (ADU)</td><td align="center" rowspan="1" colspan="1"><bold><italic>0</italic>.<italic>52&#x000b1;0</italic>.<italic>03</italic></bold><xref ref-type="table-fn" rid="t004fn002">*</xref></td><td align="center" rowspan="1" colspan="1">0.40&#x000b1;0.04</td><td align="center" rowspan="1" colspan="1">0.49&#x000b1;0.03</td><td align="center" rowspan="1" colspan="1">0.46&#x000b1;0.03</td><td align="center" rowspan="1" colspan="1">0.48&#x000b1;0.03</td><td align="center" rowspan="1" colspan="1">0.48&#x000b1;0.04</td><td align="center" rowspan="1" colspan="1">0.48&#x000b1;0.05</td><td align="center" rowspan="1" colspan="1">0.48&#x000b1;0.02</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>AVD = aortic valve disease, CAT = catalase, DLP = dyslipidemia, MDA = malondialdehyde, MnSOD = manganese superoxide dismutase, MVD = mitral valve disease, NO = nitric oxide, O<sub>2</sub><sup>.-</sup> = superoxide anion, TAC = total antioxidant capacity, 3-NT = nitrotyrosine.</p></fn><fn id="t004fn002"><p>* <bold><italic>p</italic></bold> &#x0003c; 0.05 values were calculated using the Mann Whitney test.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec022"><title>Discussion</title><p>In this study, <italic>in vitro</italic> preparations of right atrial appendages from a very large cohort of patients undergoing elective heart surgery were examined with respect to I/R and IPreC. The results demonstrated that: (1) the response of the human myocardium to I/R is highly variable, with tissue from patients with aortic valve disease being more susceptible to injury than tissue from patients with other cardiac pathologies. By contrast, the myocardial tissue of patients with dyslipidemia was the least susceptible to I/R injury. (2) The response to IPreC was also highly variable. The myocardium from females was significantly better protected than that from males and, the myocardium from patients with mitral valve disease was less responsive to IPreC-mediated protection than tissues from patients without mitral valve disease. (3) The redox status of the myocardium under basal conditions (prior to ischemia) may be relevant to the degree of I/R-induced injury and to the response to IPreC in patients with heart valve pathologies.</p><p>Since, for obvious ethical reasons, the effect of I/R-induced injury on human myocardium cannot be investigated in clinical settings, we took advantage of a well characterized <italic>in vitro</italic> model [<xref rid="pone.0174588.ref008" ref-type="bibr">8</xref>] and were able to show large differences in the response of the human myocardium to I/R, ranging from slight to severe injury after 90 min of ischemia and 120 min of reoxygenation (<xref ref-type="fig" rid="pone.0174588.g002">Fig 2A2 and 2B2</xref>). The greater susceptibility of myocardial tissue from patients with aortic valve disease to I/R injury is consistent with previous reports showing that myocardial hypertrophy causes extensive I/R injury in animal experimental preparations [<xref rid="pone.0174588.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0174588.ref014" ref-type="bibr">14</xref>] and in humans [<xref rid="pone.0174588.ref015" ref-type="bibr">15</xref>]. Our finding is of particular interest because the prevalence of left ventricular (LV) hypertrophy is 20&#x02013;25% in the general population [<xref rid="pone.0174588.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0174588.ref017" ref-type="bibr">17</xref>] and 50% in patients with previous myocardial infarction [<xref rid="pone.0174588.ref018" ref-type="bibr">18</xref>].</p><p>The increased extracellular collagen matrix of the hypertrophied myocardium together with its decreased capillary density could make patients with LV hypertrophy more susceptible to I/R injury. Furthermore, carbohydrate metabolism is altered in the hypertrophied left ventricle, which may contribute to an increased susceptibility to I/R injury, by causing disturbances in ion homeostasis. Earlier reports showed that the hypertrophied myocardium exhibits an accelerated loss of high-energy phosphate content and a greater accumulation of tissue lactate and hydrogen ions during ischemia as well as an accelerated calcium overload during early reperfusion [<xref rid="pone.0174588.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0174588.ref020" ref-type="bibr">20</xref>]. It should be noted that the infarct size in patients with LV hypertrophy may be significantly overestimated when based on the determination of cardiac enzymes such as the peak and AUC plasma values of cardiac troponin I [<xref rid="pone.0174588.ref021" ref-type="bibr">21</xref>]. In the present study, the results were expressed based on the weight of the myocardial tissue, thus avoiding this source of potential error.</p><p>The effect of hypercholesterolemia, a risk factor for cardiovascular disease, on I/R-induced injury is controversial and the mechanisms involved are not well understood [<xref rid="pone.0174588.ref022" ref-type="bibr">22</xref>]. Both the type of experimental preparation used and the duration of the hypercholesterolemic diet in animal models may influence the degree of I/R-induced injury. Our results showed that the myocardium from patients with established dyslipidemia is less susceptible to injury. However, the majority of the patients in our study (95%) were taking HMG-CoA reductase inhibitors (statins), which in addition to reducing serum cholesterol exert pleiotropic effects that could have influenced the susceptibility of the myocardium to I/R injury [<xref rid="pone.0174588.ref023" ref-type="bibr">23</xref>]. Experimental studies have implicated an increase in oxidative stress and a diminished bioavailability in NO in the altered response to I/R injury in hypercholesterolemia [<xref rid="pone.0174588.ref024" ref-type="bibr">24</xref>]. Our assessment of oxidative and nitrosative stress basal status in human myocardium was unable to demonstrate its direct relationship with the degree of I/R injury in the myocardium of patients with hypercholesterolemia. Therefore, it cannot be argued that the diminished susceptibility to I/R injury of the myocardium from patients with dyslipidemia is due to changes in the basal redox status of the tissue.</p><p>The wide spectrum of responses of human myocardium to IPreC (<xref ref-type="fig" rid="pone.0174588.g003">Fig 3A and 3B</xref>), including the increased damage in 22% of IPreC-treated myocardial samples, calls into question the clinical utility of this intervention, at least when used indiscriminately. A univariate analysis of the various pathologies, comorbidities, and medical treatment revealed a better myocardial response to IPreC in female than in male patients, consistent with the well-established sex-related differences in the response to global injury in humans [<xref rid="pone.0174588.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0174588.ref027" ref-type="bibr">27</xref>]. The mechanisms responsible for the higher degree of protection by IPreC in females have yet to be fully elucidated but seem to involve estrogens [<xref rid="pone.0174588.ref028" ref-type="bibr">28</xref>&#x02013;<xref rid="pone.0174588.ref030" ref-type="bibr">30</xref>] and estrogen receptor-&#x003b1; [<xref rid="pone.0174588.ref031" ref-type="bibr">31</xref>]. Furthermore, endothelial nitric oxide synthase expression is higher in females than in males [<xref rid="pone.0174588.ref032" ref-type="bibr">32</xref>], suggesting that higher levels of NO play a role in the better cardioprotective potential of IPreC. Nonetheless, in our study neither the myocardial NO content nor the antioxidant status differed between females and males under basal conditions.</p><p>Another important finding of our study was the lower susceptibility of the myocardium from patients with mitral valve disease to IPreC protection. The increased pressure within the left atrium and pulmonary vasculature characteristic of mitral valve disease may lead to hypertrophy and dilation of the right heart [<xref rid="pone.0174588.ref033" ref-type="bibr">33</xref>], which would contribute to a reduced response to IPreC. The clinical importance of our findings lies in the fact that patients undergoing mitral valve surgery may be less responsive to cardioprotective therapies and at greater risk of perioperative myocardial injury, leading to heart failure. These patients may therefore require additional protective measures during heart surgery. The underlying mechanisms for the diminished response to IPreC in the presence of mitral valve disease are unknown. Cavalca et al. [<xref rid="pone.0174588.ref034" ref-type="bibr">34</xref>] reported an increase in the levels of oxidative stress markers in the serum of patients with mitral valve disease, but in our study, with the exception of the increased myocardial MnSOD levels, there were no significant differences in other indexes of tissue redox status under basal conditions (see below).</p><p>There is ample evidence in the literature of both the involvement of free radicals in the injury sustained during I/R and the benefit of interventions aimed at reducing their production. To the best of our knowledge, this is the first study to investigate whether the basal redox status of the myocardium influences the response to I/R-induced injury and the protective effect of IPreC. Our results demonstrated a role for basal redox status in the response to I/R injury and IPreC by the myocardium of patients with certain cardiac pathologies. Although the reason for the greater susceptibility to I/R injury of myocardium from patients with aortic valve disease is unclear, it may be that the increased myocardial catalase content reflects the body&#x02019;s attempt to combat the excess oxidative stress. This would explain the decreased TAC levels, indicative of the consumption of antioxidants and thus of an increased susceptibility of the myocardium to I/R injury. The greater MnSOD content in the myocardium of patients with mitral valve disease, which is less responsive to protection by IPreC, is difficult to interpret. A possible explanation is that the resulting greater ability to mop up free radicals eliminates a critical trigger leading to the induction of IPreC. This conclusion is supported by a report in which IPreC was experimentally induced by oxygen radicals [<xref rid="pone.0174588.ref035" ref-type="bibr">35</xref>] but protection was attenuated by antioxidants [<xref rid="pone.0174588.ref036" ref-type="bibr">36</xref>]. Alternatively, the elevated MnSOD in the myocardial tissue of patients with mitral valve disease may be a natural response in line with the higher levels of oxidative stress markers in the serum of these patients [<xref rid="pone.0174588.ref034" ref-type="bibr">34</xref>]. It should be noted that in the present study redox status was determined in myocardial tissue, where it did not correlate with comorbidities, as opposed to plasma, in which elevated levels of oxidative and nitrosative stress markers have been determined in patients with diabetes [<xref rid="pone.0174588.ref037" ref-type="bibr">37</xref>], atherosclerosis, hypertension, and heart failure [<xref rid="pone.0174588.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0174588.ref038" ref-type="bibr">38</xref>]. Whether anti-free radical therapies should be aimed at controlling the redox status in blood rather than in tissues remains to be examined in further investigations.</p><p>A major contribution of this study is its demonstration that the response to I/R and protective interventions such as IPreC by the diseased myocardium is neither uniform nor predictable, which may at least in part explain the failure to translate cardioprotective therapies into useful clinical treatments. Our results indicate the need for caution in the broad clinical use of IPreC and instead emphasize the importance of further studies, using relevant human disease models, to fully identify the molecular basis of I/R injury and the appropriate cardioprotective interventions in patients. These efforts will improve treatment approaches in the clinical setting.</p><p>A limitation of the present study is that, for ethical reasons, only right atrial tissue and not left ventricular myocardium could be obtained. However, we [<xref rid="pone.0174588.ref039" ref-type="bibr">39</xref>] and others [<xref rid="pone.0174588.ref040" ref-type="bibr">40</xref>] have demonstrated that the myocardium from the two cardiac chambers responds similarly to I/R and IPreC. Nonetheless, it remains possible that cardiac valve pathologies differentially affect the cardiac chambers and thereby influence the myocardial response to I/R and cardioprotective therapies. Another limitation was that the study was performed <italic>in vitro</italic> using isolated myocardial tissue; therefore, our results cannot necessarily be extrapolated to clinical conditions. Nonetheless, the laboratory model used in this study provides a safe, rapid, and inexpensive system for testing and refining protective interventions in human myocardium impaired by various comorbidities and/or exposed to medical treatment, before they are considered for clinical use.</p></sec><sec sec-type="conclusions" id="sec023"><title>Conclusions</title><p>The response of the myocardium from patients with heart diseases to I/R and IPreC varies widely and may be influenced by specific cardiac pathologies and the sex of the patient. Our results do not support the broad clinical use of IPreC; rather, they emphasize the need for research into both the molecular basis of I/R-induced injury and the cardioprotective interventions in human myocardium that will lead to clinical success. Whether the basal redox status of the myocardium plays a role in the degree of I/R-induced injury and the response to IPreC remains to be determined. Our results are an important contribution to the design of future clinical studies on I/R injury and IPreC.</p></sec><sec sec-type="supplementary-material" id="sec024"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0174588.s001"><label>S1 File</label><caption><p>Table A. Mean values for lactate dehydrogenase (LDH) and 3-(4,5-dimethyl thiazol-2-yl)-2,5diphenyl tetrazolium bromide (MTT) in human right atrial appendage (n = 300). Table B. Conditions affecting the susceptibility to ischemia/reperfusion (I/R)-induced injury. No statistically significant differences where observe between groups. Table C. Conditions affecting the capacity of protection by ischemic preconditioning. No statistically significant differences where observe between groups.</p><p>(DOCX)</p></caption><media xlink:href="pone.0174588.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We are grateful to the surgeons from the Department of Cardiac Surgery at the University Hospital Vall d'Hebron (Barcelona) for harvesting the right atrial appendage and to Dr. Xavier Vidal for help with the statistical analyses.</p></ack><ref-list><title>References</title><ref id="pone.0174588.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Zweier</surname><given-names>JL</given-names></name>, <name><surname>Talukder</surname><given-names>MA</given-names></name> (<year>2006</year>) <article-title>The role of oxidants and free radicals in reperfusion injury</article-title>. <source>Cardiovasc Res</source>
<volume>70</volume>: <fpage>181</fpage>&#x02013;<lpage>190</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cardiores.2006.02.025">10.1016/j.cardiores.2006.02.025</ext-link></comment>
<pub-id pub-id-type="pmid">16580655</pub-id></mixed-citation></ref><ref id="pone.0174588.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Kalogeris</surname><given-names>T</given-names></name>, <name><surname>Baines</surname><given-names>CP</given-names></name>, <name><surname>Krenz</surname><given-names>M</given-names></name>, <name><surname>Korthuis</surname><given-names>RJ</given-names></name> (<year>2012</year>) <article-title>Cell biology of ischemia/reperfusion injury</article-title>. <source>Int Rev Cell Mol Biol</source>
<volume>298</volume>: <fpage>229</fpage>&#x02013;<lpage>317</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/B978-0-12-394309-5.00006-7">10.1016/B978-0-12-394309-5.00006-7</ext-link></comment>
<pub-id pub-id-type="pmid">22878108</pub-id></mixed-citation></ref><ref id="pone.0174588.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Cao</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>T</given-names></name>, <name><surname>Yu</surname><given-names>S</given-names></name>, <name><surname>Sun</surname><given-names>G</given-names></name>, <name><surname>Gu</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Relationships of adiponectin with markers of systemic inflammation and insulin resistance in infants undergoing open cardiac surgery</article-title>. <source>Mediators Inflamm</source>: <fpage>187940</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2013/187940">10.1155/2013/187940</ext-link></comment>
<pub-id pub-id-type="pmid">23840093</pub-id></mixed-citation></ref><ref id="pone.0174588.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Genereux</surname><given-names>P</given-names></name>, <name><surname>Cohen</surname><given-names>DJ</given-names></name>, <name><surname>Mack</surname><given-names>M</given-names></name>, <name><surname>Rodes-Cabau</surname><given-names>J</given-names></name>, <name><surname>Yadav</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Incidence, predictors, and prognostic impact of late bleeding complications after transcatheter aortic valve replacement</article-title>. <source>J Am Coll Cardiol</source>
<volume>64</volume>: <fpage>2605</fpage>&#x02013;<lpage>2615</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jacc.2014.08.052">10.1016/j.jacc.2014.08.052</ext-link></comment>
<pub-id pub-id-type="pmid">25524339</pub-id></mixed-citation></ref><ref id="pone.0174588.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Hawkes</surname><given-names>AL</given-names></name>, <name><surname>Nowak</surname><given-names>M</given-names></name>, <name><surname>Bidstrup</surname><given-names>B</given-names></name>, <name><surname>Speare</surname><given-names>R</given-names></name> (<year>2006</year>) <article-title>Outcomes of coronary artery bypass graft surgery</article-title>. <source>Vasc Health Risk Manag</source>
<volume>2</volume>: <fpage>477</fpage>&#x02013;<lpage>484</lpage>. <pub-id pub-id-type="pmid">17323602</pub-id></mixed-citation></ref><ref id="pone.0174588.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Furnary</surname><given-names>AP</given-names></name>, <name><surname>Gao</surname><given-names>G</given-names></name>, <name><surname>Grunkemeier</surname><given-names>GL</given-names></name>, <name><surname>Wu</surname><given-names>Y</given-names></name>, <name><surname>Zerr</surname><given-names>KJ</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting</article-title>. <source>J Thorac Cardiovasc Surg</source>
<volume>125</volume>: <fpage>1007</fpage>&#x02013;<lpage>1021</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1067/mtc.2003.181">10.1067/mtc.2003.181</ext-link></comment>
<pub-id pub-id-type="pmid">12771873</pub-id></mixed-citation></ref><ref id="pone.0174588.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Juranek</surname><given-names>I</given-names></name>, <name><surname>Bezek</surname><given-names>S</given-names></name> (<year>2005</year>) <article-title>Controversy of free radical hypothesis: reactive oxygen species&#x02014;cause or consequence of tissue injury?</article-title>
<source>Gen Physiol Biophys</source>
<volume>24</volume>: <fpage>263</fpage>&#x02013;<lpage>278</lpage>. <pub-id pub-id-type="pmid">16308423</pub-id></mixed-citation></ref><ref id="pone.0174588.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>JG</given-names></name>, <name><surname>Ghosh</surname><given-names>S</given-names></name>, <name><surname>Ockleford</surname><given-names>CD</given-names></name>, <name><surname>Gali&#x000f1;anes</surname><given-names>M</given-names></name> (<year>2000</year>) <article-title>Characterization of an in vitro model for the study of the short and prolonged effects of myocardial ischaemia and reperfusion in man</article-title>. <source>Clin Sci (Lond)</source>
<volume>99</volume>: <fpage>443</fpage>&#x02013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">11052925</pub-id></mixed-citation></ref><ref id="pone.0174588.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Ghosh</surname><given-names>S</given-names></name>, <name><surname>Standen</surname><given-names>NB</given-names></name>, <name><surname>Gali&#x000f1;anes</surname><given-names>M</given-names></name> (<year>2000</year>) <article-title>Evidence for mitochondrial K ATP channels as effectors of human myocardial preconditioning</article-title>. <source>Cardiovasc Res</source>
<volume>45</volume>: <fpage>934</fpage>&#x02013;<lpage>940</lpage>. <pub-id pub-id-type="pmid">10728419</pub-id></mixed-citation></ref><ref id="pone.0174588.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Penna</surname><given-names>C</given-names></name>, <name><surname>Mancardi</surname><given-names>D</given-names></name>, <name><surname>Rastaldo</surname><given-names>R</given-names></name>, <name><surname>Pagliaro</surname><given-names>P</given-names></name> (<year>2009</year>) <article-title>Cardioprotection: a radical view Free radicals in pre and postconditioning</article-title>. <source>Biochim Biophys Acta</source>
<volume>1787</volume>: <fpage>781</fpage>&#x02013;<lpage>793</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbabio.2009.02.008">10.1016/j.bbabio.2009.02.008</ext-link></comment>
<pub-id pub-id-type="pmid">19248760</pub-id></mixed-citation></ref><ref id="pone.0174588.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Zuo</surname><given-names>L</given-names></name>, <name><surname>Roberts</surname><given-names>WJ</given-names></name>, <name><surname>Tolomello</surname><given-names>RC</given-names></name>, <name><surname>Goins</surname><given-names>AT</given-names></name> (<year>2013</year>) <article-title>Ischemic and hypoxic preconditioning protect cardiac muscles via intracellular ROS signaling</article-title>. <source>Frontiers in Biology</source>
<volume>8</volume>: <fpage>305</fpage>&#x02013;<lpage>311</lpage>.</mixed-citation></ref><ref id="pone.0174588.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>F</given-names></name>, <name><surname>Zuo</surname><given-names>L</given-names></name> (<year>2015</year>) <article-title>Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases</article-title>. <source>Int J Mol Sci</source>
<volume>16</volume>: <fpage>27770</fpage>&#x02013;<lpage>27780</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/ijms161126059">10.3390/ijms161126059</ext-link></comment>
<pub-id pub-id-type="pmid">26610475</pub-id></mixed-citation></ref><ref id="pone.0174588.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Anderson</surname><given-names>PG</given-names></name>, <name><surname>Allard</surname><given-names>MF</given-names></name>, <name><surname>Thomas</surname><given-names>GD</given-names></name>, <name><surname>Bishop</surname><given-names>SP</given-names></name>, <name><surname>Digerness</surname><given-names>SB</given-names></name> (<year>1990</year>) <article-title>Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts</article-title>. <source>Circ Res</source>
<volume>67</volume>: <fpage>948</fpage>&#x02013;<lpage>959</lpage>. <pub-id pub-id-type="pmid">2145092</pub-id></mixed-citation></ref><ref id="pone.0174588.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Menasche</surname><given-names>P</given-names></name>, <name><surname>Grousset</surname><given-names>C</given-names></name>, <name><surname>Apstein</surname><given-names>CS</given-names></name>, <name><surname>Marotte</surname><given-names>F</given-names></name>, <name><surname>Mouas</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>1985</year>) <article-title>Increased injury of hypertrophied myocardium with ischemic arrest: preservation with hypothermia and cardioplegia</article-title>. <source>Am Heart J</source>
<volume>110</volume>: <fpage>1204</fpage>&#x02013;<lpage>1209</lpage>. <pub-id pub-id-type="pmid">2933942</pub-id></mixed-citation></ref><ref id="pone.0174588.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Malek</surname><given-names>LA</given-names></name>, <name><surname>Spiewak</surname><given-names>M</given-names></name>, <name><surname>Klopotowski</surname><given-names>M</given-names></name>, <name><surname>Petryka</surname><given-names>J</given-names></name>, <name><surname>Mazurkiewicz</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Influence of left ventricular hypertrophy on infarct size and left ventricular ejection fraction in ST-elevation myocardial infarction</article-title>. <source>Eur J Radiol</source>
<volume>81</volume>: <fpage>e177</fpage>&#x02013;<lpage>181</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ejrad.2011.01.088">10.1016/j.ejrad.2011.01.088</ext-link></comment>
<pub-id pub-id-type="pmid">21324622</pub-id></mixed-citation></ref><ref id="pone.0174588.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Drazner</surname><given-names>MH</given-names></name>, <name><surname>Dries</surname><given-names>DL</given-names></name>, <name><surname>Peshock</surname><given-names>RM</given-names></name>, <name><surname>Cooper</surname><given-names>RS</given-names></name>, <name><surname>Klassen</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas Heart Study</article-title>. <source>Hypertension</source>
<volume>46</volume>: <fpage>124</fpage>&#x02013;<lpage>129</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.HYP.0000169972.96201.8e">10.1161/01.HYP.0000169972.96201.8e</ext-link></comment>
<pub-id pub-id-type="pmid">15939807</pub-id></mixed-citation></ref><ref id="pone.0174588.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Ferrara</surname><given-names>AL</given-names></name>, <name><surname>Vaccaro</surname><given-names>O</given-names></name>, <name><surname>Cardoni</surname><given-names>O</given-names></name>, <name><surname>Panarelli</surname><given-names>W</given-names></name>, <name><surname>Laurenzi</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Is there a relationship between left ventricular mass and plasma glucose and lipids independent of body mass index? Results of the Gubbio Study</article-title>. <source>Nutr Metab Cardiovasc Dis</source>
<volume>13</volume>: <fpage>126</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="pmid">12955793</pub-id></mixed-citation></ref><ref id="pone.0174588.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Carluccio</surname><given-names>E</given-names></name>, <name><surname>Tommasi</surname><given-names>S</given-names></name>, <name><surname>Bentivoglio</surname><given-names>M</given-names></name>, <name><surname>Buccolieri</surname><given-names>M</given-names></name>, <name><surname>Filippucci</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction</article-title>. <source>Int J Cardiol</source>
<volume>74</volume>: <fpage>177</fpage>&#x02013;<lpage>183</lpage>. <pub-id pub-id-type="pmid">10962119</pub-id></mixed-citation></ref><ref id="pone.0174588.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Allard</surname><given-names>MF</given-names></name>, <name><surname>Flint</surname><given-names>JD</given-names></name>, <name><surname>English</surname><given-names>JC</given-names></name>, <name><surname>Henning</surname><given-names>SL</given-names></name>, <name><surname>Salamanca</surname><given-names>MC</given-names></name>, <etal>et al</etal> (<year>1994</year>) <article-title>Calcium overload during reperfusion is accelerated in isolated hypertrophied rat hearts</article-title>. <source>J Mol Cell Cardiol</source>. <volume>12</volume>: <fpage>1551</fpage>&#x02013;<lpage>1563</lpage>.</mixed-citation></ref><ref id="pone.0174588.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Sink</surname><given-names>JD</given-names></name>, <name><surname>Pellom</surname><given-names>GL</given-names></name>, <name><surname>Currie</surname><given-names>WD</given-names></name>, <name><surname>Hill</surname><given-names>RC</given-names></name>, <name><surname>Olsen</surname><given-names>CO</given-names></name>, <etal>et al</etal> (<year>1981</year>) <article-title>Response of hypertrophied myocardium to ischemia: correlation with biochemical and physiological parameters</article-title>. <source>J Thorac Cardiovasc Surg</source>
<volume>81</volume>: <fpage>865</fpage>&#x02013;<lpage>872</lpage>. <pub-id pub-id-type="pmid">6453258</pub-id></mixed-citation></ref><ref id="pone.0174588.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Fernandez-Jimenez</surname><given-names>R</given-names></name>, <name><surname>Silva</surname><given-names>J</given-names></name>, <name><surname>Martinez-Martinez</surname><given-names>S</given-names></name>, <name><surname>Lopez-Maderuelo</surname><given-names>MD</given-names></name>, <name><surname>Nuno-Ayala</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Impact of left ventricular hypertrophy on troponin release during acute myocardial infarction: new insights from a comprehensive translational study</article-title>. <source>J Am Heart Assoc</source>
<volume>4</volume>: <fpage>e001218</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/JAHA.114.001218">10.1161/JAHA.114.001218</ext-link></comment>
<pub-id pub-id-type="pmid">25609414</pub-id></mixed-citation></ref><ref id="pone.0174588.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Gali&#x000f1;anes</surname><given-names>M</given-names></name>, <name><surname>Fowler</surname><given-names>AG</given-names></name> (<year>2004</year>) <article-title>Role of clinical pathologies in myocardial injury following ischaemia and reperfusion</article-title>. <source>Cardiovasc Res</source>
<volume>61</volume>: <fpage>512</fpage>&#x02013;<lpage>521</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cardiores.2003.11.028">10.1016/j.cardiores.2003.11.028</ext-link></comment>
<pub-id pub-id-type="pmid">14962481</pub-id></mixed-citation></ref><ref id="pone.0174588.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Correale</surname><given-names>M</given-names></name>, <name><surname>Abruzzese</surname><given-names>S</given-names></name>, <name><surname>Greco</surname><given-names>CA</given-names></name>, <name><surname>Concilio</surname><given-names>M</given-names></name>, <name><surname>Biase</surname><given-names>MD</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Pleiotropic effects of statin in therapy in heart failure: a review</article-title>. <source>Curr Vasc Pharmacol</source>
<volume>12</volume>: <fpage>873</fpage>&#x02013;<lpage>884</lpage>.</mixed-citation></ref><ref id="pone.0174588.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Csonka</surname><given-names>C</given-names></name>, <name><surname>Sarkozy</surname><given-names>M</given-names></name>, <name><surname>Pipicz</surname><given-names>M</given-names></name>, <name><surname>Dux</surname><given-names>L</given-names></name>, <name><surname>Csont</surname><given-names>T</given-names></name> (<year>2016</year>) <article-title>Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart</article-title>. <source>Oxid Med Cell Longev</source>
<volume>2016</volume>: <fpage>3863726</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2016/3863726">10.1155/2016/3863726</ext-link></comment>
<pub-id pub-id-type="pmid">26788247</pub-id></mixed-citation></ref><ref id="pone.0174588.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>KF</given-names><suffix>Jr.</suffix></name>, <name><surname>Sueta</surname><given-names>CA</given-names></name>, <name><surname>Gheorghiade</surname><given-names>M</given-names></name>, <name><surname>O'Connor</surname><given-names>CM</given-names></name>, <name><surname>Schwartz</surname><given-names>TA</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Gender differences in survival in advanced heart failure. Insights from the FIRST study</article-title>. <source>Circulation</source>
<volume>99</volume>: <fpage>1816</fpage>&#x02013;<lpage>1821</lpage>. <pub-id pub-id-type="pmid">10199877</pub-id></mixed-citation></ref><ref id="pone.0174588.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Mendelsohn</surname><given-names>ME</given-names></name>, <name><surname>Karas</surname><given-names>RH</given-names></name> (<year>1999</year>) <article-title>The protective effects of estrogen on the cardiovascular system</article-title>. <source>N Engl J Med</source>
<volume>340</volume>: <fpage>1801</fpage>&#x02013;<lpage>1811</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJM199906103402306">10.1056/NEJM199906103402306</ext-link></comment>
<pub-id pub-id-type="pmid">10362825</pub-id></mixed-citation></ref><ref id="pone.0174588.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Schwarzenberger</surname><given-names>JC</given-names></name>, <name><surname>Sun</surname><given-names>LS</given-names></name>, <name><surname>Pesce</surname><given-names>MA</given-names></name>, <name><surname>Heyer</surname><given-names>EJ</given-names></name>, <name><surname>Delphin</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Sex-based differences in serum cardiac troponin I, a specific marker for myocardial injury, after cardiac surgery</article-title>. <source>Crit Care Med</source>
<volume>31</volume>: <fpage>689</fpage>&#x02013;<lpage>693</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/01.CCM.0000055442.84685.4D">10.1097/01.CCM.0000055442.84685.4D</ext-link></comment>
<pub-id pub-id-type="pmid">12626970</pub-id></mixed-citation></ref><ref id="pone.0174588.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>TM</given-names></name>, <name><surname>Su</surname><given-names>SF</given-names></name>, <name><surname>Tsai</surname><given-names>CC</given-names></name>, <name><surname>Lee</surname><given-names>YT</given-names></name>, <name><surname>Tsai</surname><given-names>CH</given-names></name> (<year>2000</year>) <article-title>Cardioprotective effects of 17 beta-estradiol produced by activation ofmitochondrial ATP-sensitive K(+)Channels in canine hearts</article-title>. <source>J Mol Cell Cardiol</source>
<volume>32</volume>: <fpage>1147</fpage>&#x02013;<lpage>1158</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1006/jmcc.2000.1167">10.1006/jmcc.2000.1167</ext-link></comment>
<pub-id pub-id-type="pmid">10860759</pub-id></mixed-citation></ref><ref id="pone.0174588.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Tsai</surname><given-names>BM</given-names></name>, <name><surname>Reiger</surname><given-names>KM</given-names></name>, <name><surname>Brown</surname><given-names>JW</given-names></name>, <name><surname>Meldrum</surname><given-names>DR</given-names></name> (<year>2006</year>) <article-title>17-beta-Estradiol decreases p38 MAPK-mediated myocardial inflammation and dysfunction following acute ischemia</article-title>. <source>J Mol Cell Cardiol</source>
<volume>40</volume>: <fpage>205</fpage>&#x02013;<lpage>212</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yjmcc.2005.06.019">10.1016/j.yjmcc.2005.06.019</ext-link></comment>
<pub-id pub-id-type="pmid">16427650</pub-id></mixed-citation></ref><ref id="pone.0174588.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Zhai</surname><given-names>P</given-names></name>, <name><surname>Eurell</surname><given-names>TE</given-names></name>, <name><surname>Cotthaus</surname><given-names>R</given-names></name>, <name><surname>Jeffery</surname><given-names>EH</given-names></name>, <name><surname>Bahr</surname><given-names>JM</given-names></name>, <etal>et al</etal> (<year>2000</year>) <article-title>Effect of estrogen on global myocardial ischemia-reperfusion injury in female rats</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<volume>279</volume>: <fpage>H2766</fpage>&#x02013;<lpage>2775</lpage>. <pub-id pub-id-type="pmid">11087231</pub-id></mixed-citation></ref><ref id="pone.0174588.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Crisostomo</surname><given-names>P</given-names></name>, <name><surname>Wairiuko</surname><given-names>GM</given-names></name>, <name><surname>Meldrum</surname><given-names>DR</given-names></name> (<year>2006</year>) <article-title>Estrogen receptor-alpha mediates acute myocardial protection in females</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<volume>290</volume>: <fpage>H2204</fpage>&#x02013;<lpage>2209</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpheart.01219.2005">10.1152/ajpheart.01219.2005</ext-link></comment>
<pub-id pub-id-type="pmid">16415070</pub-id></mixed-citation></ref><ref id="pone.0174588.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>J</given-names></name>, <name><surname>Picht</surname><given-names>E</given-names></name>, <name><surname>Ginsburg</surname><given-names>KS</given-names></name>, <name><surname>Bers</surname><given-names>DM</given-names></name>, <name><surname>Steenbergen</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury</article-title>. <source>Circ Res</source>
<volume>98</volume>: <fpage>403</fpage>&#x02013;<lpage>411</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.RES.0000202707.79018.0a">10.1161/01.RES.0000202707.79018.0a</ext-link></comment>
<pub-id pub-id-type="pmid">16397145</pub-id></mixed-citation></ref><ref id="pone.0174588.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Chandrashekhar</surname><given-names>Y</given-names></name>, <name><surname>Westaby</surname><given-names>S</given-names></name>, <name><surname>Narula</surname><given-names>J</given-names></name> (<year>2009</year>) <article-title>Mitral stenosis</article-title>. <source>Lancet</source>
<volume>374</volume>: <fpage>1271</fpage>&#x02013;<lpage>1283</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(09)60994-6">10.1016/S0140-6736(09)60994-6</ext-link></comment>
<pub-id pub-id-type="pmid">19747723</pub-id></mixed-citation></ref><ref id="pone.0174588.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Cavalca</surname><given-names>V</given-names></name>, <name><surname>Tremoli</surname><given-names>E</given-names></name>, <name><surname>Porro</surname><given-names>B</given-names></name>, <name><surname>Veglia</surname><given-names>F</given-names></name>, <name><surname>Myasoedova</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Oxidative stress and nitric oxide pathway in adult patients who are candidates for cardiac surgery: patterns and differences</article-title>. <source>Interact Cardiovasc Thorac Surg</source>
<volume>17</volume>: <fpage>923</fpage>&#x02013;<lpage>930</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/icvts/ivt386">10.1093/icvts/ivt386</ext-link></comment>
<pub-id pub-id-type="pmid">24014619</pub-id></mixed-citation></ref><ref id="pone.0174588.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Tritto</surname><given-names>I</given-names></name>, <name><surname>D'Andrea</surname><given-names>D</given-names></name>, <name><surname>Eramo</surname><given-names>N</given-names></name>, <name><surname>Scognamiglio</surname><given-names>A</given-names></name>, <name><surname>De Simone</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>1997</year>) <article-title>Oxygen radicals can induce preconditioning in rabbit hearts</article-title>. <source>Circ Res</source>
<volume>80</volume>: <fpage>743</fpage>&#x02013;<lpage>748</lpage>. <pub-id pub-id-type="pmid">9130455</pub-id></mixed-citation></ref><ref id="pone.0174588.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Skyschally</surname><given-names>A</given-names></name>, <name><surname>Schulz</surname><given-names>R</given-names></name>, <name><surname>Gres</surname><given-names>P</given-names></name>, <name><surname>Korth</surname><given-names>HG</given-names></name>, <name><surname>Heusch</surname><given-names>G</given-names></name> (<year>2003</year>) <article-title>Attenuation of ischemic preconditioning in pigs by scavenging of free oxyradicals with ascorbic acid</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<volume>284</volume>: <fpage>H698</fpage>&#x02013;<lpage>703</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1152/ajpheart.00693.2002">10.1152/ajpheart.00693.2002</ext-link></comment>
<pub-id pub-id-type="pmid">12388272</pub-id></mixed-citation></ref><ref id="pone.0174588.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Pacher</surname><given-names>P</given-names></name>, <name><surname>Obrosova</surname><given-names>IG</given-names></name>, <name><surname>Mabley</surname><given-names>JG</given-names></name>, <name><surname>Szabo</surname><given-names>C</given-names></name> (<year>2005</year>) <article-title>Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies</article-title>. <source>Curr Med Chem</source>
<volume>12</volume>: <fpage>267</fpage>&#x02013;<lpage>275</lpage>. <pub-id pub-id-type="pmid">15723618</pub-id></mixed-citation></ref><ref id="pone.0174588.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Heistad</surname><given-names>DD</given-names></name> (<year>2006</year>) <article-title>Oxidative stress and vascular disease: 2005 Duff lecture</article-title>. <source>Arterioscler Thromb Vasc Biol</source>
<volume>26</volume>: <fpage>689</fpage>&#x02013;<lpage>695</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.ATV.0000203525.62147.28">10.1161/01.ATV.0000203525.62147.28</ext-link></comment>
<pub-id pub-id-type="pmid">16410455</pub-id></mixed-citation></ref><ref id="pone.0174588.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Linares-Palomino</surname><given-names>J</given-names></name>, <name><surname>Husainy</surname><given-names>MA</given-names></name>, <name><surname>Lai</surname><given-names>VK</given-names></name>, <name><surname>Dickenson</surname><given-names>JM</given-names></name>, <name><surname>Gali&#x000f1;anes</surname><given-names>M</given-names></name> (<year>2010</year>) <article-title>Selective blockade of protein kinase B protects the rat and human myocardium against ischaemic injury</article-title>. <source>J Physiol</source>
<volume>588</volume>: <fpage>2173</fpage>&#x02013;<lpage>2191</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1113/jphysiol.2010.190462">10.1113/jphysiol.2010.190462</ext-link></comment>
<pub-id pub-id-type="pmid">20403980</pub-id></mixed-citation></ref><ref id="pone.0174588.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Speechly-Dick</surname><given-names>ME</given-names></name>, <name><surname>Grover</surname><given-names>GJ</given-names></name>, <name><surname>Yellon</surname><given-names>DM</given-names></name> (<year>1995</year>) <article-title>Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model</article-title>. <source>Circ Res</source>
<volume>77</volume>: <fpage>1030</fpage>&#x02013;<lpage>1035</lpage>. <pub-id pub-id-type="pmid">7554138</pub-id></mixed-citation></ref></ref-list></back></article>